FAQ About the IOM Report on the CTSA Program
- Why was the Institute of Medicine (IOM) report commissioned?
- What did the IOM report recommend?
- How will NCATS respond to the report’s findings and recommendations?
- How will the report and its implementation affect the institutions with currently funded CTSA grants?
- Who was on the IOM committee?
NIH commissioned the report in response to a congressional request in the fiscal year 2012 Appropriation Conference Report. The report "urge[d] NIH to support a study by the Institute of Medicine to evaluate the CTSA program and to recommend whether changes to the current mission are needed."
The IOM committee made a number of recommendations after obtaining input from a broad spectrum of stakeholders. The report provides additional detail about each area but provides seven high-level recommendations.
- Strengthen the leadership of the CTSA program by NCATS
- Reconfigure and streamline the CTSA Consortium
- Build on the strengths of individual CTSAs across the spectrum of clinical and translational research
- Formalize and standardize the evaluation processes for individual CTSAs and the CTSA program
- Advance innovation in education and training programs
- Ensure community engagement in all phases of research
- Strengthen clinical and translational research relevant to child health
NCATS has assembled a working group of stakeholders to provide advice as the Center begins rapid implementation the report's recommendations. One of the first tasks will be development of clear, measurable goals and objectives for the program that address critical issues across the full spectrum of clinical and translational research. While engaging with stakeholders, NCATS also is increasing its direct and active leadership of the CTSA program, including addressing the recommendation to streamline program governance.
How will the report and its implementation affect the institutions with currently funded CTSA grants?
NCATS is committed to supporting the current CTSA grantees. There will be opportunities for dialogue and planning with current grantees and other stakeholders to ensure any changes to the program are communicated and implemented in a clear, strategic and organized fashion.
The IOM appointed a 13-member committee with a broad range of expertise and experience. The committee was chaired by Alan Leshner, Ph.D., CEO of the American Association for the Advancement of Science and executive publisher of the organization's journal, Science, and Sharon Terry, M.A., president and CEO of the Genetic Alliance, a network of more than 10,000 organizations, of which 1,200 are disease advocacy organizations. View a list of the IOM committee members on the IOM website.